HISTOLOGICAL-EVALUATION OF BENIGN PROSTATIC HYPERPLASIA TREATED BY LONG-TERM ADMINISTRATION OF CHLORMADINONE ACETATE (CMA)

被引:16
作者
HARADA, M
KINOSHITA, Y
MORIYAMA, M
KONDO, I
NAKAHASHI, M
KUMAGAI, H
SASAKI, K
HOSAKA, M
机构
[1] YOKOHAMA CITY UNIV,SCH MED,DEPT UROL,YOKOHAMA,KANAGAWA,JAPAN
[2] KANAGAWA CANC CTR HOSP,DEPT UROL,YOKOHAMA,KANAGAWA,JAPAN
[3] YOKOHAMA SEAMENS INSURANCE HOSP,DIV UROL,YOKOHAMA,KANAGAWA,JAPAN
[4] KANAGAWA PREFECTURAL ASHIGARA KAMI HOSP,DEPT UROL,MATSUDO,KANAGAWA,JAPAN
[5] YAMATO MUNICIPAL HOSP,DEPT UROL,YAMATO,NARA,JAPAN
关键词
HISTOLOGICAL EFFECT; BENIGN PROSTATIC HYPERPLASIA; CHLORMADINONE ACETATE;
D O I
10.1002/pros.2990250306
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although the clinical effects of attempted nonsurgical treatment of benign prostatic hyperplasia have been well documented, detailed histological evaluation of the effects of treatment appears to be limited. The effect of long-term administration of an antiandrogen, chlormadinone acetate (CMA), on benign prostatic hyperplasia was evaluated with histological comparison of two biopsy specimens, one before treatment and one after treatment. Secretory epithelium showed obvious regressive changes with occasional basal cell prominence after CMA treatment. Stromal elements, however, did not show any marked changes, except for occasional edematous loosening. Scores of multiple epithelial parameters tended to be correlated with clinical improvement in urinary obstructive symptoms, especially in patients with predominant glandular hyperplasia. These results suggest that long-term administration of the potent antiandrogen CMA to inhibit dihydrotestosterone-receptor binding might be a useful therapeutic maneuver in patients with glandular hyperplasia, without any deterioration of the stromal component. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码:147 / 155
页数:9
相关论文
共 28 条
[1]   IMMUNOHISTOCHEMICAL DISTRIBUTION OF THE 3 PREDOMINANT SECRETORY PROTEINS IN THE PARENCHYMA OF HYPERPLASTIC AND NEOPLASTIC PROSTATE-GLANDS [J].
ABRAHAMSSON, PA ;
LILJA, H ;
FALKMER, S ;
WADSTROM, LB .
PROSTATE, 1988, 12 (01) :39-46
[2]   LIGHT MICROSCOPIC STEREOLOGICAL ANALYSIS OF THE NORMAL HUMAN-PROSTATE AND OF BENIGN PROSTATIC HYPERPLASIA [J].
BARTSCH, G ;
MULLER, HR ;
OBERHOLZER, M ;
ROHR, HP .
JOURNAL OF UROLOGY, 1979, 122 (04) :487-491
[3]   THE DEVELOPMENT OF HUMAN BENIGN PROSTATIC HYPERPLASIA WITH AGE [J].
BERRY, SJ ;
COFFEY, DS ;
WALSH, PC ;
EWING, LL .
JOURNAL OF UROLOGY, 1984, 132 (03) :474-479
[4]  
COFFEY DS, 1990, UROL CLIN N AM, V17, P461
[5]   COMPARISON OF SPONTANEOUS AND EXPERIMENTALLY INDUCED CANINE PROSTATIC HYPERPLASIA [J].
DEKLERK, DP ;
COFFEY, DS ;
EWING, LL ;
MCDERMOTT, IR ;
REINER, WG ;
ROBINSON, CH ;
SCOTT, WW ;
STRANDBERG, JD ;
TALALAY, P ;
WALSH, PC ;
WHEATON, LG ;
ZIRKIN, BR .
JOURNAL OF CLINICAL INVESTIGATION, 1979, 64 (03) :842-849
[6]  
DERMER GB, 1978, CANCER, V41, P1857, DOI 10.1002/1097-0142(197805)41:5<1857::AID-CNCR2820410529>3.0.CO
[7]  
2-T
[8]   MULTIPLE IMMUNOPEROXIDASE MARKERS IN BENIGN HYPERPLASIA AND ADENOCARCINOMA OF THE PROSTATE [J].
ELLIS, DW ;
LEFFERS, S ;
DAVIES, JS ;
NG, ABP .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1984, 81 (03) :279-284
[9]  
FRANKS LM, 1954, ANN ROY COLL SURG, V14, P92
[10]   EFFECT OF FINASTERIDE, A 5-ALPHA-REDUCTASE INHIBITOR ON PROSTATE TISSUE ANDROGENS AND PROSTATE-SPECIFIC ANTIGEN [J].
GELLER, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (06) :1552-1555